A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells

Experimental Hematology

Volumn 24, Issue 7, 1996, Pages 823-828

  Roman Unfer, S ^a   Bitran, J D ^a   Garrison, L ^a   Proeschel, C ^a   Hanauer, S ^a   Schroeder, L ^a   Johnson, L ^a   Klein, L ^a   Martinec, J ^a  

^a Division of Hematology and Oncology   (United States)

Author keywords

Breast cancer; Mobilized peripheral blood progenitor cells; PIXY321

Indexed keywords

CD34 ANTIGEN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; FUROSEMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; MILODISTIM;

ARTHRALGIA; ARTICLE; BREAST CANCER; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; ERYTHEMA; HUMAN; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; BONE MARROW DISEASES; BREAST NEOPLASMS; COLONY-FORMING UNITS ASSAY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; LENGTH OF STAY; LEUKAPHERESIS; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0029887254     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)